The success of active cancer immunotherapy entails a robust induction of tumor-reactive effector and memory CD8 + T cells. We compared the in vivo immunogenicity of the melanoma-associated antigen Melan-A 26-35 encoded by thirdgeneration recombinant lentivector (rec. lv) or as peptide admixed with a strong adjuvant. Ex vivo analyses of immunized HLA-A2/H-2K b mice showed that rec. lv triggered a stronger anti-Melan-A CD8 + T-cell response than peptide vaccine. Importantly, the majority of anti-Melan-A T cells elicited by rec. lv expressed the memory marker CD127 at the peak of the primary response. In those mice, memory T cells were detectable several months after priming and could be activated by recall peptide vaccination. These results show that immunization with rec. lv induces not only a strong antigen-specific CD8 + T-cell response but also a long-lasting T-cell memory against a bona fide tumor-associated antigen.
Introduction
A critical goal in the development of potent vaccines against tumors and infectious agents is the ability to induce strong and long-lasting specific CTL responses. Among the many antimelanoma vaccines currently under investigation, peptide and viral vaccines hold the highest promise because of their relative ease of production and their application to a large number of patients. Recombinant viruses offer additional advantages in that they are highly immunogenic, relatively stable, and suitable for the sustained expression of one or more determinants of interest. However, the immunodominance of certain viral epitopes may mask the response against the relevant antigenic peptide. On the basis of these considerations, genetic modifications and adaptations of recombinant retroviruses have shown promising results in targeting relevant human diseases (1) (2) (3) (4) (5) . In the context of immunologic responses, several reports have described the successful transduction of dendritic cells and the high efficiency of transduced cells to induce specific T-cell responses (6) (7) (8) (9) (10) (11) (12) . Our previous work also showed that direct administration of recombinant lentivectors (rec. lv) to mice resulted in potent T-cell responses (13) .
Melan-A/MART-1 (hereafter called Melan-A), a protein expressed in melanocytes and melanomas, contains an antigenic peptide recognized by a high frequency of CD8 + T cells from HLA-A2 + melanoma patients (14) . This peptide, with sequence EAAGIGILTV, encompasses amino acids 26 to 35 of the protein.
Mutation of Ala 27 to Leu increased the affinity of the resulting peptide analogue to HLA-A2 and simultaneously augmented its immunogenicity in vitro and in vivo (15) . Importantly, CTL reactive against this mutated peptide were cross-reactive to the wild-type peptide and recognized Melan-A + tumor cells (15, 16) . For the sake of simplicity, the terminology Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] will be used throughout this work to describe the mutated Melan-A peptide.
Although Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide vaccination has been shown to induce high frequencies of specific T cells in melanoma patients (17) , it is not known if this primary T-cell response will develop into a long-lasting memory response and if this will translate into a better antitumor response. In the current study, we directly compared in HLA-A2/H-2K b transgenic mice the anti-Melan-A CD8 + T-cell response elicited by direct administration of rec. lv containing the Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] sequence with that induced by a potent Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide-adjuvant vaccine. We observed that the magnitude of the anti-Melan-A T-cell response was superior after a single immunization with rec. lv than after peptide vaccination. At the peak of the primary response elicited by rec. lv, a high proportion of specific T cells expressed the IL-7 receptor a chain (CD127), suggesting that rec. lv induced primarily precursors of memory T cells (18, 19) . In those mice, antigenspecific memory T cells were detected several months after priming and this correlated with the efficiency of the T-cell response observed after antigen recall. We conclude that rec. lv immunization favors the development of quantitatively and qualitatively superior CD8 + T-cell responses against tumorassociated antigens.
Materials and Methods
Mice. All immunizations were done using HLA-A*0201/H-2K b transgenic mice (20) . Animal experiments were carried out in pathogen-free facilities and in compliance with the rules of the local veterinary office.
Construction of recombinant lentivector. All Melan-A sequences contained the Ala to Leu substitution at position 27 to increase the affinity of the peptide to HLA-A2. The Melan-A 26-35 sequence was expressed from a UPR-based construct (21, 22) . This expression system, which exploits the natural process by which free ubiquitin is produced in all eukaryotic cells, has been previously described (23) . In brief, Melan-A 26-35 is expressed as a linear fusion with enhanced green fluorescent protein (EGFP)-ubiquitin. Shortly after translation, Melan-A 26-35 is released from EGFP-ubiquitin by the action of intracellular ubiquitin proteases. The main advantage of this system is that Melan-A 26-35 is directly released in its final form in the cytoplasm. Rec. lv were generated by inserting the DNA sequence coding for EGFP-ubiquitin-Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] between the BamHI and XbaI sites of the lentiviral transfer vector pRRLsin18.PPT.CMV. The latter vector as well as the production of recombinant lentiviruses have been described (5, 10, 13) . Details are available on request.
Synthetic peptides and CpG oligodeoxynucleotides. Peptide ELAGI-GILTV was synthesized by solid-phase chemistry and was over 90% pure (by analytic high-performance liquid chromatography). Lyophilized peptides were diluted in DMSO and stored at À20jC. Synthetic CpG-containing oligodeoxynucleotides (TCCATGACGTTCCTGACGTT) optimized for mouse vaccination (oligodeoxynucleotide 1826, Coley Pharmaceutical Group, Inc., Wellesley, MA) were dissolved in sterile PBS.
Vaccination. b tetramers was 0.5%, as assessed by analysis of CD8 + T cells from naïve mice. Other antibodies used were phycoerythrin cychrome 5.5-conjugated antiCD8a (5H10, Caltag Laboratories, Burlingame, CA), Alexa 647-conjugated anti-CD127 (47R34, prepared in our laboratory), anti-CD4 (GK1.5, produced at our institute), anti-CD44 (Pgp1, produced at our institute), and anti-Ly-6C (HK1.4, Southern Biotech, Birmingham, AL). Erythrocytes were lysed using the FACS Lysing solution (Becton Dickinson, San Jose, CA).
In vivo CTL assays. In vivo CTL assays were done as previously described (13) . Briefly, splenocytes from syngeneic mice were either pulsed with the peptide Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] for 1 hour at 37jC or left untreated. The pulsed cells (10 7 /mL) were then labeled with carboxyfluorescein diacetate succinamidyl ester (CFSE) at a concentration of 0.6 Amol/L whereas the untreated cells were labeled with CFSE at a concentration of 0.04 Amol/L CFSE. The two cell populations were mixed at a ratio of 1:1. A total of 10 7 cells per mouse were injected into the tail vein on day 14 after lentiviral immunization or on day 9 after peptide vaccination. Eighteen hours later, mice were bled and PBMC, spleens, and liver were independently collected. The disappearance of peptide-pulsed cells was determined by flow cytometry. By comparing the ratio of the pulsed (high fluorescence intensity) to the nonpulsed fraction (low fluorescence intensity), the percentage of specific killing was established according to the following equation: 100 À [(percentage pulsed) Â (percentage nonpulsed) À1 Â 100].
In vitro CTL assays. Cytotoxic activity was measured using standard 4-hour chromium release assays as previously reported (15) . EL-4A2/K b transfectants were used as target cells. Briefly, mice were bled at the peak of the response (day 14 for rec. lv immunization and day 9 for peptide immunization) and PBMC were isolated by Ficoll gradient and counted. Target cells were labeled with 51 Cr for 1 hour at 37jC in the presence or absence of 1 Amol/L Melan-A 26-35 peptide, then washed and coincubated with PBMC at the indicated PBMC to target cell ratio in V-bottomed 96-well plates in a total volume of 200 AL medium. Chromium release was measured after 4 hours of incubation at 37jC. Percentage of specific lysis was calculated as follows: % specific lysis = (experimental release À spontaneous release / total release À spontaneous release) Â 100.
Statistical analyses. Significance was assessed by using unpaired Student's t test. P < 0.05 was considered significant.
Results
Kinetics of the anti-Melan-A T-cell response in HLA-A2/ H-2K b transgenic mice. We compared the immunogenicity of rec. lv containing the preprocessed Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ). This vaccine formulation was reported to be optimal for the induction of strong CD8 + T-cell responses in vivo (24) . The magnitude of the antigenspecific responses was determined ex vivo by staining circulating CD8 + T cells with Melan-A 26-35 /A2K b tetramers (13, 24) . In mice immunized with rec. lv/Melan-A 26-35 , a significant response was first detected at day 9 and increased to reach a peak of 15.75% tetramer-positive (tet + ) T cells among total CD8 + cells at day 14 ( Fig. 1A) . Whereas the frequency of circulating tet + cells decreased thereafter, a frequency of 1.74% tet + cells was still detectable among total CD8 + T cells at day 86. The proportion of tet + cells among activated (CD62L low ) CD8 + T cells followed a similar curve (Fig. 1B) . By comparison, the frequency of tet + cells among total CD8 + T cells elicited by peptide vaccination reached 1.9% at the peak of the response (day 9) and returned to undetectable levels 28 days after priming. Among CD62L low CD8 + T cells, a proportion of tet + cells remained detectable for prolonged periods of time after adj/Melan-A 26-35 immunization (Fig. 1B) . At day 86, this proportion was similar in mice immunized with adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and in those immunized with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . However, the absolute number of tet + CD62L low cells among total CD8 + T cells detected at this time point was f4 times lower in mice immunized with adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] than in those immunized with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . These results show that a single vaccination with rec. lv induces a strong and long-lasting CD8 + T-cell response against a melanoma-associated antigen in vivo.
Recombinant lentivector immunizations induce stronger anti-Melan-A CD8 + T-cell responses than peptides. Because T-cell responses could be followed by ex vivo analysis of PBMC, we performed a detailed enumeration of the circulating T-cell populations 9 and 14 days after immunization with adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , respectively. These time points correspond to the peaks of the primary T-cell response (Fig. 1) . As shown in Table 1 , an average of 7.6% tet + cells among CD8 + T cells were detected 14 days after a single immunization with rec. lv/ Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The frequency of activated CD62L low CD8 + T cells in these mice was higher than in mice immunized with an irrelevant lv (13.1% versus 6%). However, 43.8% of the activated CD8 + T cells isolated from mice immunized with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] were tet + , indicating that the overall increase of activated T cells was due to the expansion of Melan-A specific T cells. Mice immunized with To this end, we did in vivo CTL assays using as targets peptide-pulsed syngeneic splenocytes that were injected i.v. into vaccinated mice (13) . Before injection, peptide-pulsed splenocytes were labeled with high-intensity CFSE so that their fate in vivo could be followed by flow cytometry in various tissues. As internal control, the same number of nonpulsed cells was labeled with a lower intensity of CFSE and coinjected with the peptide-pulsed cells. Eighteen hours later, the proportion of living cells with low versus high CFSE content was measured by flow cytometry and allowed us to calculate the percentage of specific target cell killing. Between 51% and 76% of the injected peptide-pulsed cells were eliminated from blood, liver, and spleen of immunized mice ( Fig. 2A) . Specific killing was similar in mice immunized with rec. lv/ Melan-A 26-35 and adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . We conclude that rec. lv and peptide immunizations induced CTL capable of performing effector functions in vivo.
To quantify more precisely the CTL response, we did ex vivo cytolytic assays. For this analysis, we chose a pair of mice that differed to the same extent in tet + CD8 + T-cell frequencies as the ones described above (Fig. 2B ). PBMC were isolated from immunized mice at the peak of the response and directly incubated with peptide-pulsed 51 Cr-labeled target cells ex vivo. At similar PBMC-target cell ratios, T cells isolated from mice immunized with rec. lv/Melan-A 26-35 lysed target cells f10 times more efficiently than cells isolated from peptide immunized mice (Fig. 2B) [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] into each group of mice described in Fig. 1 130 days after the initial vaccination. We selected peptide for the recall immunization to bypass the previously described anti-lv immunity (13) . As shown in Fig. 3A , mice primed with rec. lv/Melan-A 26-35 mounted an efficient memory-type T-cell response after peptide boost, reaching frequencies of f5% tet + cells among total CD8 + T cells. In contrast, mice primed with peptide did not respond better than untreated mice or mice primed with rec. lv/EGFP (compare with Table 1 ). These results highlight the potency of rec. lv in promoting the establishment of long-lasting CD8 + T-cell memory. As memory T cells are characterized by the expression of markers such as CD44, Ly-6C, and CD127 (18, 25), we did a phenotypic analysis of the tet + CD8 + T cells detected 86 days after immunization with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The majority of these tet + CD8
+ T cells expressed CD44 (56%), Ly-6C (86%), and CD127 (78%). In contrast, tetramer-negative CD8 + T cells isolated from the same mice did not (Fig. 3B) . Such an analysis could not be done in mice immunized with peptides because the number of tet + CD8 + T cells at day 86 was below detection (Fig. 3A) . Interestingly, 40% tet + cells also expressed CD62L (Fig. 3B) . In addition to being a marker of naïve cells, CD62L has also been shown to be expressed by memory cells. Because no circulating tet + CD62L hi cells could be detected in naïve mice or in mice immunized with irrelevant rec. lv (Fig. 4B and data not shown), we conclude that the tet + CD62L hi cells detected at day 86 could represent memory anti-Melan-A T cells. Whether the tet + CD62L low fraction defines the subset of memory T cells called effector memory cells (see Discussion) or cells that were recently activated by the possible sustained expression of Melan-A 26-35 following rec. lv immunization remains to be elucidated. However, based on the expression of the different markers described above, we conclude that a majority of tet + CD8 + T cells induced by rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] immunization and detected at day 86 are antigen-specific memory cells. Increased anti-Melan-A memory T-cell frequencies early after rec. lv/Melan-A 26-35 immunization. It was recently shown that a fraction of the antigen-specific CD8 + T cells detected at the peak of a primary response expressed the a chain of the IL-7 receptor (CD127). This fraction has been proposed to define a population of memory cell precursors that will constitute over time the pool of memory cells (18, 19) . In light of the results shown in Fig. 3 , we analyzed tet + CD8 + T cells shortly after rec. lv/ Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] immunization for the expression of CD127 (Fig. 4) . Among PBMC of the mouse immunized with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , 61% tet + cells among total CD8 + T cells were positive for CD127 at the peak of the response whereas only 25% were positive in the mouse immunized with adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Fig. 4A) . This proportion was similar for the tet + population among CD62L low T cells (Fig. 4B) . Interestingly, a similar ratio between CD127 hi and CD127 low tet + CD8 + T cells in rec. lv or peptide immunized mice was already detectable 4 days before the peak. Taken together, these results indicate that the primary T-cell response elicited by rec. lv favors the development of antigen-specific CD8 + T cells expressing CD127, which represent potential precursors of memory T cells. In contrast, peptide immunization favors the development of activated T cells with low CD127 expression, characteristic of effector T cells.
Discussion
In this study, we found that a single injection of rec. lv resulted in higher frequencies of activated Melan-A-specific CD8 + T cells than the most potent peptide vaccine currently available. Rec. lv also favored the development of antigen-specific memory T cells as shown by the higher proportion of CD127
hi Melan-A-specific T cells detected at the peak of the primary response. Circulating memory T cells remained detectable for several months and led to superior recall responses compared with peptide vaccine.
At the peak of the response, the frequency of tet + T cells induced by rec. lv immunization reached an average of 7.6% (1 in 13 circulating CD8 + T cell). In contrast, 2.1% tet + cells among CD8 + T cells were induced by adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Table 1) . Surprisingly, these different frequencies did not result into measurable differences in in vivo CTL assays because target cells were eliminated as efficiently in mice containing 1.8% or 9.8% circulating tet + cells among total CD8 + T cells (Fig. 2) . It is likely that this assay is too easily saturable to reveal such differences. Indeed, other studies showed that as few as 0.08% circulating tet + CD8
+ CTL were able to eliminate over 50% target cells in vivo (26, 27) . By contrast, the results of ex vivo CTL assays clearly indicated that the quantitative differences in circulating tet + CD8 + T cells between mice immunized with rec. lv/Melan-A 26-35 and mice immunized with adj/Melan-A 26-35 translated into different effector activities. Indeed, the increased lytic activities mediated by PBMC isolated from mice immunized with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] correlated with the increased frequency of circulating tet + CD8 + T cells. Whereas it is possible that peptide immunization might result in efficient tumor rejection in vivo, our results indicate that this vaccination modality is unlikely to induce long-lasting protective antitumor immunity. By contrast, immunization with rec. lv offers the advantage of eliciting not only a high proportion of specific effector CD8 + T cells but also long-lasting memory T cells. Therefore, we would suggest that optimized vaccines should also stimulate the development of tumor-reactive memory T cells.
The a chain of the IL-7 receptor (CD127) has been shown to be expressed both by naïve and memory CD8 + T cells and is essential for T-cell survival (28) (29) (30) (31) . Moreover, expression of the IL-7 receptor is required for the development of memory CD8 + T cells after antigen stimulation (30) . Therefore, we investigated the production of memory T cells after rec. lv immunization, taking advantage of the persistence of detectable anti-Melan-A CD8 + T cells. We found that 78% of the tet + CD8 + cells detected 86 days after priming with rec. lv were CD127 hi and displayed other characteristic memory markers, including CD44, Ly-6C, and + T cells of each recipient mouse at the peak of the response is indicated. Eighteen hours later, the disappearance of peptide-pulsed cells was determined by flow cytometry in blood, spleen, and liver. The ratio of pulsed to nonpulsed cells was used to calculate the percentage of specific killing. Seven of eight mice immunized with rec. lv and five of five mice immunized with peptide or adjuvant showed similar results. B, direct ex vivo killing activities of PBMC derived from mice immunized either with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (19) . In contrast, activated CD127 low T cells were identified as effector T cells (18) . Applying these criteria, our results indicate that at the peak of the primary response, the majority (62%) of specific T cells elicited by rec. lv/ Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] were memory T-cell precursors. In contrast, a higher proportion of effector T cells than memory T-cell precursors (79% versus 21%) was induced by peptide vaccination. One would therefore conclude that a majority of antigen-specific T cells induced by rec. lv will develop into memory T cells and that the program of memory T-cell differentiation is initiated early after priming. By extension, it is tempting to speculate that the difference in tet + cell frequencies observed among total CD8 + T cells after immunizations with rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (average of 7.6%) and adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (average of 2.1%) could be caused, at least in part, by an increase in memory T-cell precursors. The reason for the different proportions of CD127-expressing T cells induced by rec. lv or peptide immunization is currently unknown. It is possible that the sustained expression and presentation of the antigenic peptide by transduced antigen presenting cells, such as dendritic cells, may be necessary for the adequate induction of effector and memory T cells. Peptides with short in vivo half-lives may not achieve this. Alternatively, the presence of T helper epitopes encoded by rec. lv itself may function as adjuvant and may act synergistically to promote the development of CD127 hi CD8 + T cells. One possible candidate antigen for this help is the vesicular stomatitis virus G protein present at the surface of the pseudotyped rec. lv used in this study. A recent report showed that CD4 + T cells were required for the emergence of CD127 + CD8 + T cells after acute lymphocytic choriomeningitis virus infection (33) . Similarly, we observed that the induction of specific CD8 + T cells by rec. lv/Melan-A 26-35 was critically dependent on the presence of CD4 + T cells (ref. 13 and data not shown).
The kinetics of the primary response differed after rec. lv or peptide immunization. Whereas the T-cell response peaked 9 days after peptide immunization, the maximal response was reached 14 days after rec. lv administration. This result suggests that the pool of precursors mobilized following peptide vaccination could be larger than after rec. lv immunization. However, analysis of the T-cell receptor repertoire induced by rec. lv/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or adj/Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] did not provide any evidence supporting that hypothesis (data not shown). Another explanation for the delayed response in rec. lv immunized mice might be the time required for the infection of dendritic cells, expression of the antigen, and migration of the transduced dendritic cells to the draining lymph node.
We conclude that a single injection of rec. lv encoding a preprocessed melanoma-associated peptide antigen induces longlasting antigen-specific T-cell responses in vivo that include high numbers of both effector and memory CD8 + T cells. In addition, the immunogenicity of the determinant introduced into rec. lv opens the possibility of investigating antigen-specific T-cell responses directly ex vivo and offers a unique tool for the analysis of in vivo T-cell response against other tumor-relevant epitopes alone or in combinations.
